{
    "nctId": "NCT02689921",
    "briefTitle": "NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer",
    "officialTitle": "A Phase II Study of NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab (NEOADAPT)",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 7,
    "primaryOutcomeMeasure": "Evidence of Pathological Response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Ability to provide signed, written informed consent\n* Histologically or cytologically confirmed non-metastatic adenocarcinoma of the breast (stage I-II)\n* Candidate for curative-intent treatment\n* ER+ and/or PR+ and HER2-positive (Fluorescence In Situ Hybridization-positive or 3+ by Immunohistochemistry staining)\n* Life expectancy greater than 5 years\n* Left Ventricular Ejection Fraction \\> 50% at baseline (within 30 days of day 0)\n* Eastern Cooperative Oncology Group performance status \u22642\n* Absolute Neutrophil Count \\>1000/\u00b5L\n* Platelets \u226550,000/\u00b5L\n* Hemoglobin \\>8.0 g/dL,\n* Creatinine \u22643.0 x upper limit of normal (ULN)\n* Bilirubin \u22643.0 x ULN\n* Aspartate aminotransferase or Alanine aminotransferase \\<5.0 x ULN\n* Negative serum pregnancy test for women \\<12 months after the onset of menopause unless surgically sterilized\n* Agreement by women of childbearing potential and male participants with partners of childbearing potential to use a \"highly effective\", non-hormonal form of contraception or two \"effective\" forms of non-hormonal contraception by the patient and/or partner.\n\nExclusion Criteria:\n\n* Active infection\n* Presence of known metastases (stage IV disease)\n* Pregnant or lactating women\n* Prior chemotherapy or radiation therapy for the primary breast cancer\n* Concomitant malignancies or previous malignancies within the last 5 years except adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.\n* History of significant cardiac disease, cardiac risk factors or uncontrolled arrhythmias\n* Current severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary or metabolic disease including diabetes, wound healing disorders, ulcers or bone fractures)\n* Major surgical procedure or significant traumatic injury within 28 days prior to study treatment start or anticipated need for major surgery during the course of study treatment\n* Current known infection with Human Immunodeficiency Virus (HIV), Hepatitis B virus (HBV) or Hepatitis C Virus (HCV)\n* Receipt of intravenous antibiotics for infection within 14 days prior to receiving study treatment\n* Current chronic daily treatment with corticosteroids (dose \\>10 mg/day methylprednisolone equivalent) except inhaled steroids\n* Known hypersensitivity to any of the study drugs\n* Assessment by the investigator to be unable or unwilling to comply with the requirements of the protocol",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}